At the recent European Society for Pediatric Dermatology meeting, a peer-reviewed poster was presented on the clinical need and market opportunity for an effective and well-tolerated molluscum contagiosum (MC) treatment. The poster highlighted Alphyn Biologics Zabalafin Hydrogel as a drug that could potentially fill that need. Precefi, our partner in managing the Phase 2 trial of MC, presented the poster after extensive research on the market.

We look forward to sharing results of Alphyn Biologics Phase 2 trial of MC later this year.

Read More Details >